Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 7/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 5/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30474209 | 0.87 | TLR7 (0.48) | ACSS2LMNAALDH1A1 | |
| SCHEMBL25373333 | 0.87 | ACSS2 (0.42) | ACSS2AGTR1AGTR2LMNAB3GNT2 | |
| SCHEMBL25373335 | 0.87 | ACSS2 (0.42) | ACSS2AGTR1AGTR2LMNAB3GNT2 | |
| SCHEMBL27111194 | 0.78 | AGTR1 (0.42) | ACSS2AGTR1AGTR2PPARG | |
| SCHEMBL26541102 | 0.77 | LMNA (0.38) | ACSS2AGTR1AGTR2LMNAALDH1A1 | |
| SCHEMBL26237230 | 0.76 | ACSS2 (0.46) | ACSS2LMNAALDH1A1 | |
| SCHEMBL31202954 | 0.76 | ACSS2 (0.46) | ACSS2LMNAALDH1A1 | |
| SCHEMBL30233144 | 0.75 | GLP1R (0.50) | ACSS2AGTR1AGTR2ALDH1A1PPARG | |
| SCHEMBL31143264 | 0.75 | TP53 (0.50) | ACSS2ALDH1A1 | |
| SCHEMBL20266411 | 0.75 | GLP1R (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4353717-A1 | NOVEL ARYL ETHER SUBSTITUTED HETEROCYCLIC COMPOUND AS GLP1R AGONIST | Mindrank AI Ltd. (CN) | 2024-04-17 | — | — | EP | disclosed |
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | ACSS2 2661/4885AGTR1 96/4885AGTR2 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.